Source recordFED

Arch Biopartners Inc.

Federal grants & contributions· SIF Stream 1- R&D· Innovation, Science and Economic Development Canada· FY2021· $5,407,235· BN 101328227· ON

Description

This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.

Amendment chain · 4 entries

Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $6,175,000 at start, $5,407,235 after amendment #3 (−$767,765).

$6,175,000$0Original · 2020-09-01 (start date) · total $6,175,000Amendment 1 · 2021-12-13 · total $5,937,000Amendment 2 · 2022-09-20 · total $5,407,235Amendment 3 · 2023-04-04 · total $5,407,235
  • #02020-09-01$6,175,000
  • #12021-12-13$5,937,000-$238,000
  • #22022-09-20$5,407,235-$529,765
  • #32023-04-04$5,407,235
RowDateTotal value as of rowChange vs previousDescription on this row
#0 original2020-09-01(start date)$6,175,000—This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe…
#1 amendment2021-12-13$5,937,000−$238,000This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe…
#2 amendment2022-09-20$5,407,235−$529,765This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe…
#3 amendment2023-04-04$5,407,235+$0This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe…

Related records · 7

Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).

Other current agreements for the same recipient (business number 101328227)

RefDepartment · programCurrent valueFY
172-2022-2023-Q4-1003639National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms$4,000,000FY2023
172-2018-2019-Q4-919337National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms$200,000FY2019

Other recipients funded under "SIF Stream 1- R&D" by Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada (most recent first)

RefRecipientFiscal yearCurrent valueFY
033-2024-2025-Q2-819558Coveo Solutions Inc.FY2025$15,170,000FY2025
033-2024-2025-Q2-816194Kepler Communications Inc.FY2025$20,000,000FY2025
033-2024-2025-Q2-819803Pratt & Whitney Canada CorporationFY2025$11,322,000FY2025
033-2024-2025-Q1-820045Biotechnologies Aramis Inc.FY2025$40,000,000FY2025
033-2023-2024-Q3-514239Edesa Biotech Research, Inc.FY2024$23,000,000FY2024

Cite as: Glassbox record view · Federal grants & contributions · 033-2020-2021-Q3-513415 · retrieved 2026-11-16.